Sai Life Sciences announced its financial results for the first quarter ended June 30, 2026, reporting a 12% year-on-year increase in revenue to ₹554 crore. Net profit also saw a significant rise of 22% to ₹73 crore. The company highlighted operational achievements including the launch of a new R&D facility and securing an EcoVadis Platinum Rating for sustainability.
Sai Life Sciences Reports Strong Q1 FY27 Performance
Sai Life Sciences Limited has announced robust financial results for the first quarter of Fiscal Year 2027 (Q1FY27), which concluded on June 30, 2026. The company reported a notable 12% year-on-year growth in Revenue from Operations, reaching ₹554 crore, up from ₹496 crore in the same period last year. This growth was observed across both its Contract Research (CRO) and Contract Development and Manufacturing Organization (CDMO) businesses.
Profitability and Key Metrics
Profitability also saw a significant uplift, with EBITDA increasing by 18% to ₹148 crore and Profit After Tax (PAT) rising by 22% to ₹73 crore compared to Q1FY26. The company’s EBITDA margin stood at 27% and PAT margin at 13% for the quarter. Mr. Siva Chittor, Chief Financial Officer, attributed the healthy start to FY27 to strong momentum in CRO and a strengthening CMC pipeline, which includes 33 active commercial molecules and 14 late-phase molecules.
Strategic Developments and Outlook
Commenting on the performance, Mr. Krishna Kanumuri, Managing Director and CEO, expressed satisfaction with the quarter’s progress and the evolving demands of large pharmaceutical companies seeking scientifically led, integrated outsourcing partners. He emphasized that Sai Life Sciences’ combination of technology, talent, and culture positions it well for strategic engagements that will drive long-term growth.
Key highlights from the quarter include the operationalization of a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad. Additionally, Sai Life Sciences achieved the prestigious EcoVadis Platinum Rating for sustainability, placing it among the top 1% of companies assessed worldwide. The company remains confident in executing its long-term growth strategy, supported by an FTE-led engagement model and a healthy balance sheet.
Earnings Call Details
Sai Life Sciences will host an earnings call on August 7, 2026, from 4:00 PM to 5:00 PM IST to discuss these results. Participants can join the call using the provided dial-in numbers.
Source: BSE
